Terns Pharmaceuticals to Host Investor Webinar on Promising Leukemia Drug TERN-701
Table of Contents
FOSTER CITY,Calif. – August 21, 2025 – Terns Pharmaceuticals, Inc. (Nasdaq: TERN) today announced plans for an investor webinar focused on TERN-701,an investigational therapy for chronic myeloid leukemia (CML). The webinar precedes the anticipated release of Phase 1 clinical trial data later this year.
About TERN-701 and the CARDINAL Trial
TERN-701 is a next-generation, oral inhibitor of BCR-ABL, a protein frequently overactive in CML. It uniquely targets the ABL myristoyl pocket, offering a potentially best-in-class profile for patients.The ongoing CARDINAL trial (NCT06163430) is a Phase 1 study evaluating the drug’s safety, tolerability, and efficacy in individuals with previously treated CML.
The CARDINAL trial, a global, multi-center study, initially completed its dose escalation phase in January 2025. Researchers observed no dose-limiting toxicities at the maximum dose of 500 mg daily. The dose expansion phase began in April 2025, randomizing patients to receive either 320 mg or 500 mg of TERN-701 daily, with up to 40 participants per group. Terns anticipates reporting comprehensive efficacy and safety data, including six-month major molecular response rates, in the fourth quarter of 2025.
Preliminary data from the dose escalation phase revealed encouraging molecular responses even at the lowest dose, observed in patients with heavily pre-treated CML and high baseline BCR-ABL levels. The drug also demonstrated a favorable safety profile, with no treatment discontinuations or dose reductions attributed to adverse events.
Did You Know? CML is a type of cancer that starts in the bone marrow and affects the blood and bone marrow. It is characterized by an overproduction of white blood cells.
Webinar Details
The investor webinar is scheduled for Wednesday, September 3, 2025, at 4:30 p.m.ET. The event will feature presentations from Amy Burroughs, chief executive officer; emil Kuriakose, M.D., chief medical officer; and Scott Harris, chief growth officer of Terns Pharmaceuticals.
Event details:
- event: TERN-701: Investor Educational Webinar
- Date & Time: September 3, 2025, at 4:30 p.m.ET
- Registration: Register Here
- Webcast Access: http://ir.ternspharma.com
A replay of the webinar will be available on the Terns Pharmaceuticals investor relations website.
Key Trial Data Summary
| Trial Phase | Status | Key Findings |
|---|---|---|
| phase 1 (Dose Escalation) | Completed (January 2025) | No dose-limiting toxicities observed up to 500mg QD |
| Phase 1 (Dose Expansion) | ongoing (Initiated April 2025) | Evaluating 320mg and 500mg QD doses; ~40 patients per arm |
| Data Release | Expected Q4 2025 | 6-month major molecular response rates will be reported |
Pro Tip: Major molecular response (MMR) is a notable milestone in CML treatment, indicating a substantial reduction in cancer cells.
About Terns Pharmaceuticals
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing innovative small-molecule therapies for serious diseases,including cancer and obesity. Beyond TERN-701, the company’s pipeline includes a small-molecule GLP-1 receptor agonist, a THR-β agonist, and a preclinical GIPR modulator program. The company prioritizes the development of a GIPR antagonist candidate.
Do you think novel approaches to targeting BCR-ABL, like TERN-701’s myristoyl pocket inhibition, will substantially improve outcomes for CML patients? What are the biggest challenges in developing effective therapies for chronic myeloid leukemia?
Understanding Chronic Myeloid Leukemia
CML is a slowly progressing blood cancer that affects adults. It is caused by a genetic mutation called the Philadelphia chromosome, which leads to the production of the BCR-ABL protein. Treatment options have evolved significantly over the past two decades, with tyrosine kinase inhibitors (TKIs) becoming the standard of care. However, some patients develop resistance to TKIs, highlighting the need for new therapies like TERN-701. The development of allosteric inhibitors, targeting different sites on the BCR-ABL protein, represents a promising strategy to overcome resistance and improve treatment outcomes (National Cancer Institute).
Frequently Asked Questions about TERN-701
- What is TERN-701? TERN-701 is an investigational drug being developed by Terns Pharmaceuticals for the treatment of chronic myeloid leukemia.
- How does TERN-701 work? It is an allosteric BCR-ABL inhibitor that targets the ABL myristoyl pocket.
- What is the CARDINAL trial? It’s a Phase 1 clinical trial assessing the safety and efficacy of TERN-701 in CML patients.
- When will the Phase 1 data be released? Terns Pharmaceuticals expects to release data in the fourth quarter of 2025.
- What are the potential benefits of TERN-701? It may offer a best-in-class profile and address resistance to existing CML treatments.
Disclaimer: this article is for informational purposes only and does not constitute medical or investment advice. Consult with a qualified healthcare professional or financial advisor before making any decisions related to your health or investments.
We hope this article provides valuable insight into Terns Pharmaceuticals’ progress with TERN-701. If you found this information helpful, please share it with your network! We also welcome your comments and questions below. Don’t forget to subscribe to our newsletter for the latest updates in pharmaceutical research and development.
